$ALLO 🚨 ALLO Price Alert - Up 2.32% - Cause:
- April 13, 2026: Allogene Therapeutics reported positive interim futility analysis results from the pivotal Phase 2 ALPHA3 trial of cema-cel (alloCAR T) in MRD-guided first-line consolidation for large B-cell lymphoma (LBCL/DLBCL). The readout met expectations and passed the analysis threshold.
- April 13, 2026: The company issued an official update confirming the interim futility analysis outcome for the ALPHA3 study in lymphoma therapy.
No other significant non-price, non-sentiment, non-technical events were identified in the monitored period.
ALLOUSDT
دائم
0.10753
+0.43%